Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and B16 Melanoma

resiquimod has been researched along with B16 Melanoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goto, M; Kamiya, N; Kozaka, S; Sakuragi, M; Tahara, Y; Wakabayashi, R1
Caisová, V; Chmelař, J; Jochmanová, I; Kopecký, J; Krejčová, G; Kvardová, K; Masáková, K; Nedbalová, P; Paďouková, L; Uher, O; Ženka, J1
Cooper, ZA; Dai, Z; Huang, XF; Hwu, P; Khong, H; Overwijk, WW; Singh, M; Vasilakos, JP; Wargo, JA1
Caisová, V; Chmelař, J; Glaserová, S; Husníková, H; Jochmanová, I; Kopecký, J; Krejčová, G; Kumžáková, Z; Paďouková, L; Vácová, N; Vieru, A; Wolf, KI; Ženka, J1
Chang, BA; Cross, JL; Dutz, JP; Najar, HM1
Akira, S; Diebold, SS; Morel, Y; Paturel, C; Rajagopal, D; Uematsu, S1
Bosio, C; Dow, S; Guth, A; Izzo, A; Jordan, M; Kedl, R; Sellins, K; Zaks, K1

Other Studies

7 other study(ies) available for resiquimod and B16 Melanoma

ArticleYear
Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
    Molecular pharmaceutics, 2018, 03-05, Volume: 15, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; Drug Carriers; Drug Compounding; Female; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Immunogenicity, Vaccine; Melanoma, Experimental; Membrane Proteins; Mice; Mice, Inbred C57BL; Nanoparticles; Oils; Peptide Fragments; Skin Neoplasms; Treatment Outcome

2018
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
    International immunopharmacology, 2018, Volume: 59

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Female; Imidazoles; Immunotherapy; Lipopolysaccharides; Lymphocytes, Tumor-Infiltrating; Mannans; Melanoma, Experimental; Mice, Inbred C57BL; Neutrophils; Pancreatic Neoplasms; Phagocytosis; Poly I-C; Teichoic Acids; Toll-Like Receptors; Tumor Burden

2018
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Nov-01, Volume: 193, Issue:9

    Topics: Adaptive Immunity; Animals; Antibodies, Monoclonal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL2; CTLA-4 Antigen; Cytotoxicity, Immunologic; Imidazoles; Immunity, Innate; Injections, Intralesional; Leukocytes; Lymphocytes, Tumor-Infiltrating; Melanoma; Melanoma, Experimental; Mice; Nitric Oxide; Phenotype; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden

2014
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
    BMC cancer, 2016, 12-07, Volume: 16, Issue:1

    Topics: Animals; Cytokines; Disease Models, Animal; Female; Imidazoles; Immunity, Innate; Immunotherapy; Ligands; Mannans; Melanoma, Experimental; Mice; Neoplasms; Neutrophil Infiltration; Neutrophils; Phagocytosis; Poly I-C; Respiratory Burst; Toll-Like Receptors

2016
Topical resiquimod promotes priming of CTL to parenteral antigens.
    Vaccine, 2009, Sep-25, Volume: 27, Issue:42

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Animals; Cross-Priming; Cytokines; Female; Imidazoles; Immunity, Cellular; Injections, Subcutaneous; Melanoma, Experimental; Mice; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic; Toll-Like Receptor 7; Toll-Like Receptor 8

2009
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Blood, 2010, Mar-11, Volume: 115, Issue:10

    Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Cancer Vaccines; Dendritic Cells; Dose-Response Relationship, Drug; Imidazoles; Imiquimod; Interferon Type I; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; Receptor, Interferon alpha-beta; RNA; Toll-Like Receptor 7; Tumor Cells, Cultured

2010
Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
    Journal of immunology (Baltimore, Md. : 1950), 2006, Jun-15, Volume: 176, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; Animals; Cancer Vaccines; Cations; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Priming; Female; Imidazoles; Lipopolysaccharides; Liposomes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Mycobacterium tuberculosis; Myeloid Differentiation Factor 88; Oligodeoxyribonucleotides; Ovalbumin; Poly I-C; Signal Transduction; Toll-Like Receptor 3; Toll-Like Receptor 9; Zymosan

2006